Thus CPK screening may be suggested in primary care as an approach in suspected early diagnosis of dystrophinopathy in resource limited settings which should be followed by a confirmatory molecular diagnostic approach, which will further reduce the diagnostic delay. The gene discussed is PIK3C2A; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.